Table 1.
Basic characteristics of the included studies (RCT and CCT).
| Included trials | Funding | Study designs | Study region | Sample characteristics type; male/female; age(y) | Interventions | Duration | Fever improvement time(d) | Outcome index | Intergroup differences | Adverse reactions | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Trial | Control | Trial | Control | |||||||||
| YAO 0206 (Yao et al., 2020) | CCT | Hubei | CT:21 M: 16, F: 5 57.1 ± 14.0 |
CT: 21 M: 12, F: 9 62.4 ± 12.3 |
Chinese patent drug+WT1.2.6.7 | WT1.2.6.7 | T: 4.6 ± 3.2 C: 6.1 ± 3.1 |
1. Disappearance rate of fever and cough 2. Disappearance rate of fatigue 3. Fever improvement time 4. Disappearance rate of anhelation, expectoration 5. Disappearance rate of sore throat, choking sensation in chest, dyspnea, headache, nausea, anorexia, diarrhea, muscle pain 6. Death rate |
1.P<0.05 2.P>0.05 3.P>0.05 4.P<0.05 5.P>0.05 6.Not mentioned |
|||
| LV 0217 (Lv et al., 2020) | CCT | Hubei | MT, CT: 63 M: 28, F: 35 59.1 ± 15.61 |
MT, CT: 38 M: 18, F: 20 60.2 ± 17.01 |
Chinese patent drug +WT1.2.3.5.7.8 |
WT1.2.3.5.7.8 | 10 d | T: 6 (median) C: 7 (median) |
1. Disappearance rate of fever, fatigue, cough 2. Disappearance rate of anhelation, moist rale 3. Fever improvement time 4. Disappearance rate of muscle pain, expectoration, nasal obstruction, nasal discharge, sore throat, choking sensation in chest, dyspnea, headache, nausea, vomiting, anorexia, diarrhea 5. Aggravation rate 6. Death rate |
1.P<0.05 2.P<0.05 3.P>0.05 4.P>0.05 5.P>0.05 6. Not mentioned |
No adverse response | |
| XIA 0218 (Xia et al., 2020) | √ | CCT | Hubei | CT: 27 ST: 7 M: 17, F: 17 54.18 ± 13.08 |
CT: 13 ST: 5 M: 6, F: 12 53.67 ± 12.70 |
decoction+WT1.2.7.8 | WT1.2.7.8 | 7–10 d | T: 2.64 ± 1.31 C: 4.38 ± 1.90 |
1. Fever improvement time 2. Recovery time of cough, fatigue, dyspnea, diarrhea) 3. Score of TCM syndrome scale 4. Incidence of mild type to severe type 5. Improvement rate of lung CT 6. Death rate |
1.P<0.01 2.P<0.01 3.P<0.05 4.<0.05 5.P>0.05 6. Trial 0%; Control 5.6% |
No adverse response |
| QU 0226 (Qv et al., 2020) | √ | CCT | Anhui | MT, CT: 40 M: 25, F: 15 40.65 ± 8.23 |
MT,CT:30 M: 16, F: 14 39.82 ± 6.40 |
Chinese patent drug+WT1.2 | +WT1.2 | 10 d | T:3.24 ± 0.89 C:5.10 ± 1.40 |
1. Improvement time of temperature, dry cough, nasal obstruction, Fever improvement time, sore throat, fatigue, diarrhea 2. Dime of nucleic acid test turning negative 3. Death rate |
1.P<0.05 2.P<0.05 3. Not mentioned |
Trail: 1 case of nausea; Control: 2 cases of nausea |
| DING 0303 (Ding et al., 2020) | RCT | Hubei | MT: 10 CT: 36 ST: 5 M: 39, F: 12 54.7 ± 21.3 |
MT: 11 CT: 34 ST: 4 M: 39, F: 10 50.8 ± 23.5 |
decoction+WT1.2.6 | WT1.2.6 | 10 d | 1. Disappearance rate of fever, cough, choking sensation in chest and anhelation 2. Disappearance rate of nasal obstruction, abdominal pain, and diarrhea 3. Improvement rate of ESR 4. Improvement rate of CRP, IL-6 5. Improvement rate of TNF-γ, TNF-α 6. Improvement rate of lung CT 7. Liver function 8. Death rate |
1.P<0.05 2.P>0.05 3.P<0.01 4.P<0.05 5.P>0.05 6.P<0.05 7.P>0.05 8. Not mentioned |
|||
| SHI 0305 (Shi et al., 2020) | √ | CCT | Shanghai | MT: 1 CT: 40 ST: 8 M: 26, F: 23 47.94 ± 14.46 |
MT: 1 CT: 14 ST: 3 M: 10, F: 8 46.72 ± 17.40 |
Chinese patent drug+decoction+WT1.2.3.8 | WT1.2.3.8 | 6 d | T: 16 (4,42) C: 17.5 (8,42) |
1. Clinical syndrome integral 2. Hospitalization time 3. Course of disease, fever improvement time 4. Improvement rate of lung CT 5. Death rate |
1.P<0.05 2.P<0.05 3.P>0.05 4.P>0.05 5. Not mentioned |
|
| XIAO 0310 (Xiao et al., 2020) | CCT | Hubei | MT: 100 M: 64, F: 36 60.90 ± 8.70 |
MT: 100 M: 66, F: 34 62.20 ± 7.50 |
Chinese patent drug+WT1 | WT1 | 2 w | T: 2.25 ± 1.12 C: 3.08 ± 1.64 |
1. Total effective rate 2. Lung CT 3. Fever improvement time 4. Disappearance time of cough, fatigue, dizziness, nasal discharge 5. WBC, Lymph% 6. Death rate |
1.P<0.05 2.P<0.05 3.P<0.05 4.P>0.05 5.P<0.05 6. Not mentioned |
Trail: 1 case of drug allergy: 2 cases of abdominal pain and diarrhea; Control: 2 cases of drug allergy, 1 case of abdominal pain and diarrhea |
|
| CHENG 0311 (Cheng et al., 2020) | CCT | Hubei | CT: 51 M: 26, F: 25 55.5 ± 12.3 |
CT: 51 M: 27, F: 24 55.8 ± 11.6 |
Chinese patent drug+WT1.2.8 | WT1.2.8 | 7 d | T:2.9 ± 1.7 C:3.9 ± 1.3 |
1. Disappearance rate and time of fever, fatigue, cough 2. Effective rate of main symptoms 3. Disappearance rate of expectoration, anhelation, choking sensation in chest, anorexia 4. Disappearance rate of muscle pain, dyspnea, nausea 5. Improvement rate of lung CT 6. Rate of turn to severe type 7. Death rate |
1.P<0.05 2.P<0.05 3.P<0.05 4.P>0.05 5.P>0.05 6.P<0.05 7. Not mentioned |
||
| FU 0320 (Fu et al., 2020) | √ | CCT | Hubei | CT: 37 M: 19, F: 18 45.26 ± 7.25 |
CT: 36 M: 19, F: 17 44.68 ± 7.45 |
Chinese patent drug+WT1.7 | WT1.7 | 10–15 d | 1. Accumulated points of fever, cough, dry throat and sore throat, choking sensation in chest and anhelation, fatigue 2. Effective rate, hospital discharge rate 3. Absolute value of LYM, CRP 4. WBC, LYM ratio 5. Death rate |
1.P<0.05 2.P<0.05 3.P<0.05 4.P>0.05 5. Not mentioned |
No adverse response | |
| WANG 0323 (Wang Y. et al., 2020) | √ | RCT | Hubei | MT, CT: 10 M: 5, F: 5 54.90 ± 3.71 |
MT,CT:10 M:5.F:5 55.90 ± 3.71 |
decoction,incense+WT1. | WT 1.2.8. | 7 d | 1. Clinical symptoms improved conditions (fatigue, cough, dry throat, short of breath) 2. Lung CT 3. Nucleic acid test turning negative 4. Death rate |
1.P<0.05 2.P>0.05 3.P>0.05 4. Not mentioned |
||
| DUAN 0324 (Duan et al., 2020) | √ | CCT | Hubei | MT: 82 M: 39, F: 43 51.99 ± 13.88 |
MT:41 M:23.F:18 50.29 ± 13.17 |
Chinese patent drug+WT1.2.6.7 | WT1.2.6.7 | 5 d | 1. Disappearance condition of fever 2. Disappearance time of fatigue, cough, expectoration, diarrhea 3. Disappearance time of aversion to cold, bodily pain, sore throat, pharyngalgia, dry throat 4. Score of TCM syndrome scale 5. Hamilton Anxiety Scale 6. Death rate |
1.P<0.01 2.P<0.05 3.P>0.05 4.P<0.01 5.P<0.01 6. Not mentioned |
Trail: 27 cases of diarrhea Control: no adverse response |
|
| YANG 0414 (Yang Z. et al., 2020) | √ | CCT | Hubei | ST: 51 M: 28, F: 23 61.57 ± 1.84 |
ST: 52 M: 24, F: 28 66.35 ± 1.82 |
decoction+Chinese patent drug+WT1.2.6.7 | WT1.2.6.7 | 1. CRP 2. Albumin 3. Cases number of absorption and improvement by lung CT 4. Cure rate 5. Death rate |
1.P<0.01 2.P<0.05 3.P<0.05 4.P>0.05 5. Trial 21.6%; Control 30.77% |
Trail: 2 cases of mild gastrointestinal reactions |
||
MT, mild type; CT, common type; ST, serious type; WT, western treatment.
WT: 1. antiviral; 2. anti-infection/anti-inflammatory/antibiotics; 3. immunoregulation; 4. gastrointestinal regulation; 5. relieving cough and asthma; 6. oxygen therapy; 7. glucocorticoid; 8. nutritional support; 9. nlgesics; 10. liver protection; 11. anti-anxiety.